DBV Technologies (DBVT) Depreciation & Amortization (CF) (2020 - 2026)
DBV Technologies (DBVT) reported Depreciation & Amortization (CF) of $900000.0 for Q1 2026, down 10.0% year-over-year from $1.0 million in Q1 2025, and up 30.43% quarter-over-quarter from $690000.0 in Q4 2025.
DBV Technologies (DBVT) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $900000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $900000.0, down 10.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 million (up 13963.64% YoY), and the FY2025 annual result was $3.2 million, up 445.3% from the prior year.
- Depreciation & Amortization (CF) rose to $900000.0 in Q1 2026 per DBVT's latest filing, from $690000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $12.0 million in Q4 2022 and troughed at -$10.9 million in Q4 2023.
- A 5-year average of $137235.3 and a median of $597000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) tumbled 3056.88% in 2023, then jumped 1786.79% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $12.0 million in 2022, then plunged by 190.88% to -$10.9 million in 2023, then soared by 105.84% to $638000.0 in 2024, then gained by 8.15% to $690000.0 in 2025, then surged by 30.43% to $900000.0 in 2026.
- Business Quant data shows DBVT's Depreciation & Amortization (CF) at $900000.0 in Q1 2026, $690000.0 in Q4 2025, and $792000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn | 900,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 900,000.00 |
| Mar 31, 2026 | 900,000.00 |
| Dec 31, 2025 | 690,000.00 |
| Dec 31, 2025 | 690,000.00 |
| Sep 30, 2025 | 792,000.00 |
| Sep 30, 2025 | 792,000.00 |
| Jun 30, 2025 | 712,000.00 |
| Jun 30, 2025 | 712,000.00 |
| Mar 31, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 638,000.00 |
| Dec 31, 2024 | 638,000.00 |
| Sep 30, 2024 | -152,000.00 |
| Sep 30, 2024 | -152,000.00 |
| Jun 30, 2024 | -1.46 Mn |
| Jun 30, 2024 | -1.46 Mn |
| Mar 31, 2024 | 53,000.00 |
| Mar 31, 2024 | 53,000.00 |
| Dec 31, 2023 | -10.93 Mn |
| Dec 31, 2023 | -10.93 Mn |